FDA Would Establish Conditions For Swift Manufacturing Changes
This article was originally published in The Tan Sheet
Executive Summary
FDA draft “conditions established” guidance proposes to smooth the way for continual improvement of manufacturing processes for drugs and biologics by saying which manufacturing changes are exempt from reporting to the agency.